Arbutus announces four abstracts accepted for presentation at aasld - the liver meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis b virus ab-101 clinical data abstract recognized as a poster of distinction warminster, pa., oct. 07, 2025 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that three abstracts featuring imdusiran data and one abstract featuring ab-101 data, have been accepted for poster presentations at the american association for the study of liver diseases (“aasld”) – the liver meeting 2025, taking place november 7–11 in washington, dc.
ABUS Ratings Summary
ABUS Quant Ranking